Recombinant Human Endostatin Market

Recombinant Human Endostatin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Recombinant Human Endostatin: Introduction

Endostatin is an angiogenesis inhibitor that might interfere with the pro-angiogenic action of growth factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF/FGF-2). It is a widely researched angiogenesis receptor and has antiangiogenic activity and induces microvascular endothelial cell apoptosis. Endostatin is expressed at high levels in the lungs, kidneys, and liver.
Recombinant human endostatin is a recombinant human proteolytic fragment of the C-terminal end of type XVIII collagen. It may inhibit proinflammatory cytokines, thereby decreasing hepatic metastasis.

Key Drivers of Global Recombinant Human Endostatin Market

The global recombinant human endostatin market is primarily driven by a rise in the number of research & development activities to identify potential applications of recombinant human endostatin, increase in the demand for new breakthrough treatment for cancer and ongoing studies determining potential of the collagen, which promises a breakthrough in the treatment of cancer.
Rise in prevalence of cancer is projected to fuel the market. According to the World Health Organization (WHO), around 18.1 million new cases of cancer were recorded in 2018, with 9.6 million deaths due to the disease
Globally, 1 in every 3 people is affected by cancer, with 8.8 million deaths registered in 2015 due to cancer. According to WCRF, 57% of all the cancers (except non-melanoma skin cancer) occur in the less developed countries and 43% in developed countries.

Medical Application Segment to Account for Major Share of Global Market

In terms of application, the global recombinant human endostatin market can be classified into medical application and scientific application
The medical application segment is anticipated to dominate the global recombinant human endostatin market during the forecast period, due to need for new cancer treatment and increase in awareness about use of recombinant human endostatin among healthcare professionals such as physicians and oncologists

North America to Dominate Global Recombinant Human Endostatin Market

In terms of region, the global recombinant human endostatin market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global recombinant human endostatin market during the forecast period.
The market in North America is anticipated to be driven by an increase in number of prominent pharmaceutical & biotechnology companies evaluating the use of recombinant human endostatin along with current cancer treatment drugs and a rise in expenditure on research based on the use of recombinant technology

Key Players Operating in Global Market

The global recombinant human endostatin market is highly fragmented, with a large number of domestic players accounting for major market share. Key players operating in the global recombinant human endostatin market include: